🇺🇸 FDA

Company profile · Sponsor

BRIGHT

BRIGHT MINDS BIOSCIENCES INC.

DRUG · NYSE pharma NEW YORK, NY, USA
Pipeline
24
Drugs
2
Patents
8

Quick answer

BRIGHT (DRUG) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker DRUG
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001827401

Pipeline (24)

Search pipeline →

  1. 10-week smoking cessation group therapy combined with NicoDerm CQ

    BRIGHT

    Tobacco Use Cessation

    phase 3 other completed

    1 trial

  2. Active referral

    BRIGHT

    Smoking

    phase 3 other active

    1 trial

  3. Acyclovir

    BRIGHT

    HIV Infections

    phase 3 small molecule completed

    1 trial

  4. Adderall-XR

    BRIGHT

    Cannabis Use Disorder

    phase 3 small molecule completed

    1 trial

  5. Agitated Saline SoC

    BRIGHT

    Right-To-Left Shunt

    phase 3 small molecule active

    1 trial

  6. B007

    BRIGHT

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  7. B007

    BRIGHT

    Primary Membranous Nephropathy

    phase 3 small molecule active

    2 trials

  8. B013+Nab-Paclitaxel

    BRIGHT

    Triple Negative Breast Cancer (TNBC)

    phase 3 small molecule completed

    1 trial

  9. Bedaquiline

    BRIGHT

    Multi-drug Resistant Tuberculosis

    phase 3 small molecule active

    1 trial

  10. Behavior Therapy

    BRIGHT

    HCV Negative Status

    phase 3 other completed

    1 trial

  11. Behavior Therapy

    BRIGHT

    Substance-Related Disorders

    phase 3 other completed

    3 trials

  12. Behavior Therapy

    BRIGHT

    Marijuana Abuse

    phase 3 other completed

    1 trial

  13. Behavior Therapy

    BRIGHT

    Behavior Therapy

    phase 3 other completed

    1 trial

  14. Behavioral Drug and HIV Risk Reduction Counseling

    BRIGHT

    Opiate Dependence

    phase 3 other completed

    1 trial

  15. Bias retraining

    BRIGHT

    Alcohol Use Disorder

    phase 3 other completed

    1 trial

  16. Booster Sessions

    BRIGHT

    Skill Development of Staff

    phase 3 other completed

    1 trial

  17. Brief Strategic Family Therapy (BSFT)

    BRIGHT

    Substance Abuse

    phase 3 other completed

    1 trial

  18. Brief advice

    BRIGHT

    Drug Abuse

    phase 3 other completed

    1 trial

  19. Brief motivational intervention

    BRIGHT

    Drug Use

    phase 3 other completed

    1 trial

  20. Buprenorphine

    BRIGHT

    Heroin Dependence

    phase 3 small molecule completed

    2 trials

  21. Buprenorphine

    BRIGHT

    Opioid-use Disorder

    phase 3 small molecule active

    1 trial

  22. Buprenorphine

    BRIGHT

    Cocaine-Related Disorders

    phase 3 small molecule completed

    5 trials

  23. Buprenorphine + Naltrexone

    BRIGHT

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  24. Buprenorphine +OTP

    BRIGHT

    Heroin Addiction

    phase 3 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. fluticasone propionate

    FLUTICASONE PROPIONATE

    TOPICAL approved

  2. fondaparinux sodium

    ARIXTRA

    SUBCUTANEOUS approved

    B01AX05

Patents (8)

Search patents →

  1. US 12383631

    Immune antigen specific IL-18 immunocytokines and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12350120

    Gum-protecting and teeth-whitening strip and preparation method thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12220447

    Proteolytic enzyme composition

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12173062

    Modified TNF-α antibodies and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12115136

    Fortified CBD oil for treatment of PTSD

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12097230

    Method and composition for treating post operative conditions

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11925686

    Materials for phototherapies of ophthalmic diseases

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is BRIGHT?

BRIGHT (DRUG) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does BRIGHT sponsor?

We track 24 ClinicalTrials.gov-linked programs for BRIGHT, including 10-week smoking cessation group therapy combined with NicoDerm CQ and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does BRIGHT company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.